Publication: VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia
| dc.contributor.author | Sljivancanin Jakovljevic, Tamara (57207933278) | |
| dc.contributor.author | Kontic-Vucinic, Olivera (16063770000) | |
| dc.contributor.author | Nikolic, Nadja (55324775800) | |
| dc.contributor.author | Carkic, Jelena (55802211000) | |
| dc.contributor.author | Milasin, Jelena (6603015594) | |
| dc.date.accessioned | 2025-06-12T13:59:04Z | |
| dc.date.available | 2025-06-12T13:59:04Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | Objectives: Establishment of association between: (a) Val158Met COMT (G1947A) polymorphism and preeclampsia; (b) cytokines gene expression and COMT genotypes. Methods: 50 preeclampsia and 50 healthy pregnant women were enrolled. COMT genotyping was done by PCR/RFLP. TNF-α, IL-1β, and IL-6 mRNA levels were determined by Real-time PCR. Results: Variant (AA) homozygotes carried 3.7-fold increased preeclampsia odds, especially for severe (OR = 9.0, 95%CI (2.09–38.799)) and early forms (OR = 6.6, 95%CI (1.62–26.87)). AA homozygotes with PE had higher TNF-α levels compared to controls (P = 0.012). Conclusions: Val158Met COMT polymorphism increases preeclampsia risk. TNF-α expression and Val158Met COMT polymorphism have concomitant roles in PE pathogenesis. © 2020 Informa UK Limited, trading as Taylor & Francis Group. | |
| dc.identifier.uri | https://doi.org/10.1080/10641955.2020.1843663 | |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095822671&doi=10.1080%2f10641955.2020.1843663&partnerID=40&md5=d5156bab59555c2fae38105834756c41 | |
| dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/4667 | |
| dc.subject | catechol O-methyltransferase | |
| dc.subject | cytokines | |
| dc.subject | polymorphism | |
| dc.subject | Pre-eclampsia | |
| dc.title | VAL158MET catechol O-methyltransferase polymorphism contributes to the development of preeclampsia | |
| dspace.entity.type | Publication |